API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. KO /
  3. 326030.KO

Sk Biopharmaceuticals Co Ltd (326030 KO) stock market data APIs

₩100900 3200(3.3%) as of November 26, 2024
Price chart is built with Anychart

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company has collaborative research agreement with Korea Institute of Radiological and Medical Sciences for discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments. SK Biopharmaceuticals Co., Ltd. was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.

Sk Biopharmaceuticals Co Ltd Financial Data Overview

97700
100900
-
101800
96700
72600-130000
7 651 200 M
78 313 K
465 064 M
123
0.912
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '326030',
Type: 'Common Stock',
Name: 'Sk Biopharmaceuticals Co Ltd',
Exchange: 'KO',
CurrencyCode: 'KRW',
CurrencyName: 'Korean Won',
CurrencySymbol: '₩',
CountryName: 'Korea',
CountryISO: 'KR',
OpenFigi: NULL,
ISIN: 'KR7326030004',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Sk Biopharmaceuticals Co Ltd Fundamental Data is available in our Financial Data APIs

  • Net Revenue 465 064 M
  • EBITDA 57 544 M
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Sk Biopharmaceuticals Co Ltd Earnings via APIs

  • Latest Release 2024-11-07
  • EPS/Forecast 123.44

Get Sk Biopharmaceuticals Co Ltd End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Sk Biopharmaceuticals Co Ltd latest news via APIs

Veeva Systems (VEEV) Offerings Adopted by SK Life Science

Veeva Systems Inc. VEEV recently announced that SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd., is using Veeva Vault Validation Management to streamline and accelerate its valid...

SK Life Science Labs, a Subsidiary of SK Biopharmaceuticals, Presents Discovery of Oral SMARCA2 Degraders Data at 6th Annual Targeted Protein Degradation Summit

Preclinical data show SK Life Science Labs compounds have robust anti-tumor efficacy in vivo and oral leads have demonstrated potent selective degradation of SMARCA2 with selective inhibition of proli...
News API is available at any package from $19.99 See full price
Get sample of News API
Do you have any questions?
support@eodhistoricaldata.com